Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsHe (Howard) Zhang
Assistant Clinical ProfessorAbout
Research
Publications
2025
Association Between Relapse and Long-term Kidney Outcomes in IgA Nephropathy
Shen X, Chen P, Hui M, Li J, Hou W, Yang H, Li Y, Liu L, Shi S, Zhou X, Lv J, Zhang H. Association Between Relapse and Long-term Kidney Outcomes in IgA Nephropathy. Kidney Medicine 2025, 101104. DOI: 10.1016/j.xkme.2025.101104.Peer-Reviewed Original ResearchRelapse-free ratePredictors of relapseEndpoint eventsClinicopathological predictorsIgA nephropathyLong-term kidney outcomesAssociated with adverse outcomesNon-relapsing patientsNon-relapse groupCox regression analysisEnd-stage kidney diseaseCorticosteroid-induced remissionLikelihood of relapseLASSO Cox regressionIgAN relapseRelapse incidenceRelapsed patientsRelapse groupEGFR declineRelapse rateKidney outcomesProspective cohortRemissionRelapseClinicopathological indicatorsEfficacy and safety of telitacicept in IgA nephropathy and IgA vasculitis nephropathy in adolescents: a case series
Wu J, Chen P, Liu L, Shi S, Wang F, Zhong X, Lv J, Zhang H. Efficacy and safety of telitacicept in IgA nephropathy and IgA vasculitis nephropathy in adolescents: a case series. Pediatric Nephrology 2025, 1-11. PMID: 40711544, DOI: 10.1007/s00467-025-06905-z.Peer-Reviewed Original ResearchAdolescent patientsGraphical abstractA higher resolution versionMethodsThis retrospective observational studyResultsThe median ageRetrospective observational studyIgA vasculitis nephritisBaseline to follow-upAssociated with substantial reductionsMedian proteinuriaMedian eGFRTreatment discontinuationProteinuria reductionMedian ageEfficacy outcomesMonth 3TelitaciceptCase seriesAdult patientsBaseline characteristicsVasculitis nephritisAdverse eventsTreatment optionsFollow-upSubgroup analysisIgA nephropathyPredictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted-release formulation budesonide
Chen Q, Chen P, He R, Zan J, Shen X, Lv J, Zhang H. Predictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted-release formulation budesonide. Clinical Kidney Journal 2025, 18: sfaf203. PMID: 40678796, PMCID: PMC12268327, DOI: 10.1093/ckj/sfaf203.Peer-Reviewed Original ResearchLevels of Gd-IgA1Gd-IgA1Proteinuria reductionPlasma levelsIgA nephropathyGalactose-deficient immunoglobulin A1Estimated glomerular filtration ratePredictive valueTreatment of IgA nephropathyGlomerular filtration rateIgA immune complex formationImmune complex formationProteinuria decreaseProteinuria levelsBiomarker reductionFiltration rateFollow-upTotal IgAProteinuriaRoutine visitsBaseline levelsIgANPlasma samplesMonthsRelease formulationCausal relationships between gut microbiota and IgA nephropathy: evidence from Mendelian randomization and microbiome validation
Wang X, Liu J, Huoshen W, Liu J, Qiao X, Zhang H, Zhou X. Causal relationships between gut microbiota and IgA nephropathy: evidence from Mendelian randomization and microbiome validation. Renal Failure 2025, 47: 2522979. PMID: 40563121, DOI: 10.1080/0886022x.2025.2522979.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesGut microbiotaMendelian randomizationGut microbiota speciesGut microbiota taxaMicrobiome-based interventionsMultiple-testing correctionMR analysisInverse-variance weighted methodTwo-sample Mendelian randomizationGWAS dataGut microbesAssociation studiesFunction predictionMicrobial functionsMR-Egger regressionWeighted median methodMicrobiota taxaMicrobiota speciesMicrobial shiftsMetabolic pathwaysBatch correctionMicrobiotaAcid metabolismGutEffects of Podocyte Foot Process Effacement on Kidney Prognosis and Response to Immunosuppressive Therapy in IgA Nephropathy
Guo Y, Ren Y, Shi S, Wang S, Zhou X, Liu L, Lv J, Zhu L, Zhang H. Effects of Podocyte Foot Process Effacement on Kidney Prognosis and Response to Immunosuppressive Therapy in IgA Nephropathy. Kidney Medicine 2025, 7: 101049. PMID: 40740727, PMCID: PMC12309955, DOI: 10.1016/j.xkme.2025.101049.Peer-Reviewed Original ResearchResponse to immunosuppressive therapyFoot process effacementImmunosuppressive therapyKidney prognosisSevere foot process effacementKidney outcomesRisk factorsIgA nephropathyEstimated glomerular filtration rateMonths of follow-upPodocyte injuryPeking University First HospitalComposite kidney outcomeIndependent risk factorGlomerular filtration rateImmunoglobulin A nephropathyEnd-stage kidney diseasePodocyte lesionsContinuous net reclassification improvementPodocyte foot process effacementIntegrated discrimination improvementNet reclassification improvementOverall cohortAbstractText Label="ExposureAbstractText Label="RESULTS"Role of Chimeric Antigen Receptor–Expressing Cell Therapy in Immune-Mediated Kidney Diseases: A Review
Peng J, Zhang Y, Wang J, Zhang H, Schett G. Role of Chimeric Antigen Receptor–Expressing Cell Therapy in Immune-Mediated Kidney Diseases: A Review. American Journal Of Kidney Diseases 2025, 86: 360-371. PMID: 40484342, DOI: 10.1053/j.ajkd.2025.04.012.Peer-Reviewed Original ResearchImmune-mediated kidney diseasesB-cell depletionB cellsKidney diseaseCell therapyPlasma cellsTreatment of immune-mediated kidney diseasesB-cell-depleting monoclonal antibodyB-Cell Targeted TherapiesComplete B-cell depletionAutoantibody-producing plasma cellsDeplete plasma cellsMonoclonal antibodiesAntigen-presenting cellsAdaptive immune responsesImmune-mediatedSelf-antigensT cellsImmune cellsImmune responseTherapyInfiltrated tissuesDiseaseAntibodiesCellsThe Proportion of New-Onset Microangiopathic Lesions in IgA Nephropathy is Increased After COVID-19 Pandemic in China
Wu J, Shi S, Zhou X, Liu L, Lv J, Zhu L, Wang S, Zhang H. The Proportion of New-Onset Microangiopathic Lesions in IgA Nephropathy is Increased After COVID-19 Pandemic in China. Kidney Medicine 2025, 7: 101043. PMID: 40746936, PMCID: PMC12311513, DOI: 10.1016/j.xkme.2025.101043.Peer-Reviewed Original ResearchMA lesionsCOVID-19 infectionMultivariate logistic regressionTotal biopsyRisk factorsThrombotic microangiopathyIgA nephropathyLogistic regressionStage 3Cochran-Armitage trend testDevelopment of IgANMicroangiopathic lesionsStage 2AbstractText Label="ExposureAbstractText Label="RESULTS"Stage 3aStage 3bStage 1AAbstractText Label="ConclusionsC3 depositionIgANMedical recordsAbstractText Label="LimitationsBiopsyLesionsExecutive summary for the China Kidney Disease Network (CK-NET) 2017–2018 Annual Data Report
Yang C, Gao B, Wang F, Chu H, Wang J, Sun X, Zhang P, Xu H, Mao H, Xing C, Chen M, Zuo L, Wang Y, Yu F, Zhang H, Wang H, Chen J, Zhang L, Zhao M, Group C. Executive summary for the China Kidney Disease Network (CK-NET) 2017–2018 Annual Data Report. Kidney International 2025, 107: 980-984. PMID: 40404261, DOI: 10.1016/j.kint.2024.12.017.Peer-Reviewed Original ResearchExpanding the spectrum of genetic causes of DNA-specific exonuclease TREX1 variants in thrombotic microangiopathy
Song Z, Liu Z, Li M, Li Y, Li J, Lv J, Zhang H, Zhou X. Expanding the spectrum of genetic causes of DNA-specific exonuclease TREX1 variants in thrombotic microangiopathy. Kidney International 2025, 108: 317-320. PMID: 40383229, DOI: 10.1016/j.kint.2025.04.014.Peer-Reviewed Original ResearchANCA-associated vasculitisThrombotic microangiopathyIgA nephropathyTREX1 variantsMicroangiopathic lesionsSpectrum of genetic causesAnti-complement therapyRegulate immune responsesPlasma exchangeMicrovascular thrombiGenome integrityC3 glomerulopathyTailored therapyEndothelial damagePathogenic variantsMicrovascular diseaseImmune regulationImmune responseGenetic causeMicroangiopathyCoagulation pathwayTherapeutic avenuesNephropathyCytosolic DNAPatientsNew thoughts on the intestinal microbiome-B cell-IgA axis and therapies in IgA nephropathy
Dang S, Zhang X, Zhang Y, Zhang H. New thoughts on the intestinal microbiome-B cell-IgA axis and therapies in IgA nephropathy. Autoimmunity Reviews 2025, 24: 103835. PMID: 40360014, DOI: 10.1016/j.autrev.2025.103835.Peer-Reviewed Original ResearchEnd-stage renal diseaseIgA nephropathyLack of effective early diagnosisPrognosis of patientsPathogenesis of IgANPathogenic IgAIntestinal flora dysbiosisImmune milieuMucosal infectionsEffective early diagnosisRetrospective reviewChronic glomerulonephritisRenal diseaseIgA depositionChronic progressionEarly diagnosisPathological featuresTherapeutic approachesPathogenic mechanismsIgANTherapeutic initiativesIgAIgA productionMesangial regionNephropathy